LafargeHolcim and Jalalabad Liver Trust Host Free Medical Camp

In Q3 of FY 2024–25, Crown Cement's profit surged 76% year-on-year to Tk 30.20 crore, driven by a 30% revenue growth to Tk 1,192.20 crore, attributed to a 30.14% increase in sales volume and a slight 0.46% price rise. Earnings per share rose to Tk 2.03 from Tk 1.15.

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

During a high-level meeting in Dhaka, Holcim Group reaffirmed its long-term commitment to the Bangladesh market. Martin Kriegner, Holcim’s regional head for Asia, the Middle East, and Africa, emphasized the company's continued investment and highlighted the use of non-recyclable plastics as fuel at its Chhatak plant, claiming zero environmental impact.